Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 (SEL120) in Relapsed/Refractory Advanced Solid Tumors
2024-515131-30-00Phase 2Completed
- Sponsor
- Ryvu Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rvu120 in Nonhematologic neoplasms, sponsored by Ryvu Therapeutics. Primary endpoints: Safety and tolerability (Part 1 and Part 2 Group E), Recommended phase 2 dose (RP2D) and 7 more. Started Dec 2023; status: completed.
02
Drugs
rvu120
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-515131-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515131-30-00.